Drug class

The GLP-1 class

GLP-1 medications, with sourced prices, shortage reports and study results.

Last updated

Last checked · Nov 16, 2026 UTC
4approved

Approved in this class

Alphabetical by active ingredient. Approved uses depend on the specific brand and formulation.

Dulaglutide

Trulicity

FDA-approved for

  • Type 2 diabetes
  • Heart risk

Subcutaneous injection · Once weekly

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

from $389/28 days (lilly.com/lillydirect/trulicity)

Trulicity single-dose pens · LillyDirect (Eli Lilly)

Checked on lilly.com

Price conditions

self-pay, four weekly pens; published starting rate at each dose

The self-pay program requires a prescription for an approved use, age 18+, and US or Puerto Rico residence. Purchases cannot be submitted to insurance or counted toward deductibles or out-of-pocket limits. LillyDirect defines a month's supply as four single-dose pens, one a week, so a fill covers 28 days.

28-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Exenatide

Byetta (discontinued), Bydureon BCise (discontinued), Generic exenatide

FDA-approved for

  • Type 2 diabetes

Subcutaneous injection · Twice daily (Byetta); once weekly (Bydureon BCise)

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

~$422 per pen (goodrx.com/exenatide)

Generic exenatide (Amneal) · GoodRx

Checked on goodrx.com

Price conditions

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock.

Third-party reported price.

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Liraglutide

Victoza, Saxenda

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk

Subcutaneous injection · Once daily

FDA shortage reportIn shortage (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

from $349/mo (healifynow.com/saxenda)

Saxenda via HealifyNow · HealifyNow

Checked on healifynow.com

Price conditions

its Saxenda page says "From $349/month" for Saxenda (liraglutide 3 mg, weight management), and "Your first consultation is free. No insurance needed, and you only pay if you start treatment." On the same page, "Can I cancel my Saxenda plan at any time?" is answered "Yes. There are no contracts, and you can cancel from your patient portal."

A starting price: the page does not say what the figure includes or how it changes with the dose; the page prices it per month with no contracts. Its pages also list "Liraglutide From $149/mo" without saying which kind of liraglutide it is. FDA-approved product.

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety

Semaglutide

Ozempic, Wegovy, Wegovy HD, Rybelsus

FDA-approved for

  • Weight loss
  • Type 2 diabetes
  • Heart risk
  • Kidney
  • Liver

Subcutaneous injection (Ozempic, Wegovy); oral tablet (Rybelsus, oral Ozempic, Wegovy pill) · Once weekly (injectable); once daily (oral)

FDA shortage report (accessdata.fda.gov/scripts/drugshortages)

Published entry quote

$149/30 days (pharmacy.amazon.com/Novo-Nordisk-Inc-WEGOVY-1-5-MG-TABLET-Bottle-30-Tablet/dp/B0GD6568YL)

Wegovy pill via Amazon Pharmacy · Amazon Pharmacy

Checked on pharmacy.amazon.com

Price conditions

without insurance, 1.5 mg; includes the manufacturer coupon if eligible (list price $1,348.80); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Checked . Entry quotes are not estimates of ongoing treatment cost.

Prices, evidence & safety
Word for word

How GLP-1 medicines work

From the Mechanism of Action section of each manufacturer's current FDA label.

  • Ozempic: “Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors.”FDA label, revised Jun 1, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Saxenda: “Liraglutide is an acylated human GLP-1 receptor agonist with 97% amino acid sequence homology to endogenous human GLP-1(7-37). Like endogenous GLP-1, liraglutide binds to and activates the GLP-1 receptor, a cell-surface receptor coupled to adenylyl cyclase activation through the stimulatory G-protein, Gs. Endogenous GLP-1 has a half-life of 1.5 to 2 minutes due to degradation by the ubiquitous endogenous enzymes, dipeptidyl peptidase 4 (DPP-4) and neutral endopeptidases (NEP).”FDA label, revised Feb 25, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • Trulicity: “TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release.”FDA label, revised Jun 16, 2026 (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine toOn Medicare Part D, 2025
Ozempic2 mg from week 13about 1 weekNot yet: tentative onlyDec 5, 20312,044,798
Wegovy7.2 mg from week 21about 1 weekNoDec 5, 2031108,843
Rybelsus14 mg from day 61about one weekNoMay 2, 2034280,455
Victoza1.8 mg from week 3about 13 hoursYes, 8None listed6,810
Saxenda3 mg from week 5about 13 hoursYes, 3None listedNone listed
Trulicity4.5 mg from week 13about 5 daysNo, it is a biologicNot in the Orange Book582,333

How long each takes · Generics and patents · Who covers what

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.